Background: Wild-type pigs express several carbohydrate moieties on their cell sur-
| INTRODUCTION
The alpha1,3-galactosyltransferase gene knockout (GalTKO) attenuates hyperacute rejection mechanisms driven by anti-Gal antibodies. 1 However, this genetic modification alone has not enabled successful long-term survival in preclinical xenotransplantation models. In addition to terminal alpha1,3-galactose residues, pigs express several carbohydrate moieties on their cell surfaces that are recognized by human pre-formed antibodies leading to graft injury and conversely different carbohydrates on human cells are recognized by resident pig tissue cells leading to cellular sequestration. 2, 3 One such carbohydrate is N-glycolylneuraminic acid (Neu5Gc), a sialic acid molecule synthesized in pigs but not in humans. 4 This difference in carbohydrate expression 5 appears to contribute to anemia, and thrombocytopenia seen in porcine liver xenotransplantation models.
6-8
The cytidine monophosphate-N-acetylneuraminic acid hydroxylase (CMAH) enzyme catalyzes conversion of N-acetylneuraminic acid (Neu5Ac) to Neu5Gc in most mammals, including pigs and baboons.
However, due to an evolutionary mutation resulting in loss of function of CMAH, human cells express only Neu5Ac. 9 Wild-type pig liver cells including endothelial cells and Kupffer cells recognize human Neu5Ac as foreign, triggering cell adhesion, and scavenging mechanisms that contribute to thrombocytopenia and anemia. By removing the Neu5Gc antigen from pigs and leaving only Neu5Ac porcine cells should no longer identify human cells as foreign, eliminating a graft vs host type effect. Additionally, humans have pre-formed antibodies to Neu5Gc resulting in graft injury. 10 Reduced binding of human antibodies to GalTKO.Neu5Gc knockout (Neu5GcKO) pig tissues and red blood cells has been shown. 11, 12 Especially promising is the observation that solid organs from GalTKO.hCD46.Neu5GcKO pigs should have reduced human antibody binding, 13 and this has proven true on porcine bioprosthetic heart valves prepared similarly to those used clinically for valve replacements.
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In addition, phagocytosis of human platelets has been shown by porcine hepatocytes and liver sinusoidal endothelial cells in both in vitro and ex vivo models. 6, 15 While several other recognition pathways have been implicated in platelet sequestration, recent work has shown a decrease in platelet consumption ex vivo when Neu5GcKO livers were perfused with washed human platelets. 16 By disabling the CMAH gene and thus removing the Neu5Gc antigen from pigs, the Neu5Ac on human cells should no longer be identified as foreign by porcine cells. Consequently we postulated that CMAH KO in the donor pig would decrease macrophage and endothelial cell recognition of human erythrocytes and platelets and lead to reduced cell loss.
As non-human primates (NHPs) express Neu5Gc and not Neu5AC, the effect of the CMAH KO modification in pigs cannot be studied in NHP models. Here, we report the initial use of a modified pig-tohuman ex vivo xenoperfusion model to study the effects of genetically engineered Neu5GcKO porcine livers on multiple blood cell lineages in whole human blood.
| MATERIALS AND METHODS

| Animals
Ten pigs genetically engineered with α1,3-galactosyl transferase gene knockout and human membrane cofactor (GalTKO.hCD46), and 5
pigs with an additional N-glycolylneuraminic acid knockout (GalTKO. 
| Cell culture
Porcine aortic endothelial cells were isolated from GalTKO.hCD46.
Neu5GcKO experiments (n = 4) and GalTKO.hCD46 historical controls (n = 3) via scraping and plated on 0.5% gelatin coated culture flasks (Sigma-Aldrich, St. Louis, MO, USA 
| Flow cytometry verification of Neu5GcKO
The above cultured pAECs and PBMCs were assessed for Neu5Gc expression using a Neu5Gc Antibody Kit (BioLegend, San Diego, CA, USA) according to kit instructions. Samples were then read on a BD FACSVERSE (Becton Dickinson, Franklin Lakes, NJ, USA). Acquired readings were analyzed using FlowJo software (National Institutes of
Conclusions:
The lack of Neu5Gc expression attenuated erythrocyte loss but did not prevent profound early onset thrombocytopenia or platelet activation, although TXB2 levels were decreased in the presence of Neu5GcKO.
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ex vivo perfusion, liver xenotransplantation, N-glycolylneuraminic acid, sialic acids Health). Results are expressed as the group mean and SD MFI after subtraction of the isotype control.
| Experimental groups
Reference experiments using human blood in a circuit without a liver (anhepatic controls, n = 2) were performed. Three allogenic control experiments using GalTKO.hCD46 pig livers perfused with blood from GalTKO.hCD46 porcine blood donors were performed. Twelve experiments using GalTKO.hCD46 porcine livers (n = 7) and GalTKO.
hCD46.Neu5GcKO porcine livers (n = 5) were perfused with human blood (Table 1) .
| Liver procurement
Pigs between 20 and 30 kg were sedated with intramuscular keta- Institutional Review Board-approved protocols and used within 4 hours of collection. For allogenic controls, fresh whole porcine blood was collected on the day of perfusion into citrated bags.
Additional whole blood was collected prior to the day of perfusion and centrifuged to yield platelet poor plasma which was frozen and stored. This fresh frozen porcine plasma was used in allogenic experiments.
| Blood treatment and drug regimen
All human blood was diluted with blood type compatible human plasma (Indiana Blood Center, Indianapolis, IN, USA) in a 1:1 ratio, and all porcine blood for allogenic experiments was also diluted in a 1:1 ratio. Table 1 ). One anhepatic reference experiment did not receive αGPIb due to transient drug unavailability. During circuit perfusion continuous heparin infusion was titrated to maintain a target activated clotting time (ACT) >400 seconds. Continuous insulin (Midwest Veterinary Supply) infusion was titrated based on glucometer readings. Sodium bicarbonate (Midwest Veterinary Supply) boluses and/ or continuous infusion and CO 2 gas flow rate to the oxygenator were titrated based on serial arterial and venous reservoir blood gas measurements (Medtronic, Edgewater, MD, USA).
| Liver perfusion
After storage at 4°C, livers were flushed with 500 mL of room temperature Hetastarch (Midwest Veterinary Supply) to remove preservation solution and then perfused with human blood. The ex vivo perfusion circuit used is illustrated in Figure 1 . Briefly, blood was placed in a heated 37°C water-jacketed reservoir. Blood from the reservoir was pumped through an oxygenator (Dideco neonatal oxygenator; Sorin Group, Arvada, CO, USA) then pumped both through the hepatic artery and a shunt back to the reservoir. Blood from the reservoir, partially oxygenated by the circuit shunt, was
Blood is stored in a heated water-jacketed reservoir at physiologic temperature. Blood is pumped through an oxygenator and the outflow split to provide oxygenated blood to the liver via the hepatic artery and back to the reservoir via a shunt. The partially oxygenated blood in the reservoir is pumped into the portal vein. Flow and pressure measurements of the arterial and venous systems are obtained and recorded.
Outflow is collected from the suprahepatic vena cava and returned by gravity to the reservoir 
| Sampling
Blood samples were obtained from the reservoir prior to initiation of perfusion (pre), and from the venous return at 5, 15, 30, 60, 120, 240, 360, and 480 minutes, and at termination of perfusion. Blood was circulated through the system for 5 minutes before placing the liver in line, and this sample was identified as time zero.
| Hematologic analysis
Peripheral blood leukocyte, neutrophil, hemoglobin, hematocrit, and platelet levels were measured by hemocytometer (Hemavet; Drew Scientific, Miami Lakes, FL, USA) and confirmed via commercial laboratory (Antech, Rockville, MD, USA). Measurement of plasma electrolyte and liver function test values was also performed by commercial laboratory (Antech). 
| βTG and TXB2 assays
| P-selectin measurement
Expression of CD62P was measured on fixed platelets by flow cytometry as described previously. 
| Histology
Liver tissue samples were obtained prior to perfusion (pre) and at 10, 30, 60, 120, 240, 360, 480 minutes, and at termination of perfusion. Both core needle and peripheral wedge biopsies were obtained.
Samples were formalin fixed and paraffin embedded. Tissue blocks were cut to make slides for light microscopy and stained with hematoxylin and eosin.
| Statistical analysis
All data are presented as mean and SEM unless otherwise noted. For time points up to 4 hours where groups sizes were greater or equal to n = 3, two tailed t tests were used to compare groups, with a P value <.05 considered significant (GraphPad Prism software; GraphPad, Inc., 
| RESULTS
| Neu5Gc expression
Human aortic endothelial cells stained minimally for Neu5Gc 
| Graft survival and functional parameters
Successful perfusion was achieved in all experiments as evidenced by physiologic vascular pressures and flows, bile production, and potassium normalization over the first hour ( Figure S1A ). The production of ascites was noted by all livers, and grossly experiments did not appear to vary in amount produced, but this amount was not quanti- 
| Transaminase elaboration
Alanine transaminase (ALT) levels trended up but remained within the normal range in all groups ( Figure 3A ). There was no significant difference in ALT values in association with xenogeneic liver phenotype or drug regimen ( Figure 3B ). Aspartate transaminase (AST) levels increased progressively over the perfusion interval in all experiments ( Figure 3C ) and were not significantly attenuated in association with drug treatment or Neu5Gc phenotype ( Figure 3D ).
| Hematocrit
The anhepatic circuit showed a minimal decrease in hematocrit over 
| Lactate dehydrogenase
Lactate dehydrogenase levels increased above normal in the anhepatic controls, but increased twofold to threefold higher in the allogenic and xenogeneic perfusions ( Figure 5 ) with no difference observed between genotypes.
| Platelet count
Marked thrombocytopenia was noted within 5 minutes in all xeno liver perfusion experiments regardless of liver Neu5Gc phenotype, whereas platelet counts remained relatively stable in the anhepatic and allogeneic experiments ( Figure 6A ). Significantly lower platelet counts were associated with drug treatment in GalTKO.hCD46 liver perfusions (P = .0083, Group 1A vs 1B at 15 minutes), but not with GalTKO.hCD46.Neu5GcKO livers ( Figure 6B ).
| TXB2 quantification
Prolific TXB2 elaboration, reported as measured TXB2 minus baseline level (ΔTXB2), in all xenoperfusions was significantly attenuated by drug treatment that included a thromboxane synthase inhibitor in the GalTKO.hCD46 group throughout the duration of perfusion (P = .006, Group 1A vs 1B). The addition of Neu5GcKO also showed a significant decrease in ΔTXB2 in the absence of the drug regimen throughout the duration of perfusion (P = .017, Group 1B vs 2B) ( Figure 7 ). The anhepatic and allogeneic experiments showed some TXB2 elaboration as well, though much lower than the untreated xeno groups.
| Platelet activation
Beta-thromboglobulin elaboration was prolific and higher, though not significantly so, in association with Neu5GcKO without drug
F I G U R E 4 Hematocrit levels. (A)
The anhepatic circuit showed a minimal decrease in hematocrit. All xenoperfusions showed a decrease in hematocrit over the course of the perfusion. The decrease in hematocrit of the GalTKO.hCD46 group was more than that of the GalTKO.hCD46. Neu5GcKO group (P = .0003). (B) Subgroup analysis based on drug regimen showed no difference in the GalTKO.hCD46.Neu5GcKO group (Groups 2A and 2B). The GalTKO.hCD46 group with the drug regimen (Group 1A) showed improvement over the group without (Group 1B). Of note due to different perfusion lengths SE could not be calculated after 4 h treatment relative to GalTKO.hCD46, an effect that tended to be attenuated by drug treatment with or without Neu5Gc expression, although βTG elaboration increased over perfusion time in all groups ( Figure S1C ). P-selectin expression by circulating platelets increased minimally over time as compared to baseline (Δ < 10% in all perfusions). The percentage of platelets expressing P-selectin increased more steadily after 2 hours of blood circulation in the anhepatic experiments. The GalTKO.hCD46 experiments all had low levels of expression throughout (<2%); the GalTKO.hCD46.Neu5GcKO without drug regiment group had a spike in CD62P expression at 15 minutes, but otherwise was similarly low throughout ( Figure S1D ).
| Histology
Pre-perfusion biopsies showed normal liver architecture in all ex- These findings were similar in GalTKO.hCD46 and GalTKO.hCD46.
Neu5GcKO livers.
| DISCUSSION
Up until recently work in xenotransplantation has taken advantage of a small pool of genetic modifications focused on modulating the deleterious effects associated with complement, coagulation, and inflammation. While these have been helpful in attenuating F I G U R E 5 LDH levels. LDH levels were noted to increase in all experiments. An increase in LDH over time in the anhepatic experiments was likely due to hemolysis from the system. The xenoperfusions showed increased levels of LDH release pointing to increased red blood cell and hepatocyte injury in these experiments compared to the anhepatic control F I G U R E 6 Platelet counts. (A) Marked thrombocytopenia was noted within 5 min in all xenoperfusions while platelet counts remained stable in the anhepatic controls. (B) Subgroup analysis showed no difference with or without the drug regimen in the GalTKO.hCD46.Neu5GcKO cohort (Groups 2A and 2B). Platelet counts were lower in the GalTKO.hCD46 group with the drug regimen compared to without (Groups 1A and 1B) (P = .0083) hyperacute rejection, issues with platelet sequestration, anemia, and coagulation dysregulation persist 19 and are particularly prominent for the liver. 17, 20, 21 With emerging genome editing techniques, it is possible to rapidly generate pigs with a larger number of deleted, "humanized," or added genes. Meanwhile, evaluation of outcomes associated with GalTKO pig organs enables the study of the effects of "non-Gal" antigens such as Neu5Gc and β4Gal. Assessing the value of grafts and tissues with these novel genetics depends on the ability of models to test them under clinically relevant conditions. In vivo pig-to-baboon transplant models are inadequate to test the CMAH KO modification as baboons and pigs both express CMAH and thus Neu5Gc. 22 In addition, an extensive screen of nonhuman primates suggests that they are inappropriate models because porcine macrophages do not bind non-human primate cells as they do human cells, 5 a phenomenon at least partially attributable to Neu5Gc-mediated mechanisms.
F I G U R E 7 ΔTXB2 elaboration. TXB2 levels, expressed as the change from time zero (ΔTXB2), increased in all xenoperfusions to much higher than the normal range. The addition of the drug regimen to the GalTKO.hCD46 group showed a significant decrease in ΔTXB2 (P = .006). The addition of the Neu5GcKO phenotype in the absence of the drug regimen also had a significantly lower level of ΔTXB2 (P = .017). Of note due to different perfusion lengths SE could not be calculated after 4 h However, we do not have direct evidence that this occurs in our model.
In previous studies, red blood cell loss was not completely resolved by blockade of porcine sialoadhesin, demonstrating that additional mechanisms of red blood cell sequestration or lysis exist that are not Neu5Gc mediated. Our finding that red blood cell sequestration is decreased in the absence of Neu5Gc and with (though not significantly) the combination of drugs tested here suggests that one or more alternative, Neu5Gc-independent pathways exist for the sequestration of xenogeneic erythrocytes. Once defined these additional pathways of erythrocyte sequestration will likely need to be addressed.
In this study, we did not observe relative preservation of platelets in the Neu5GcKO group. Porcine Kupffer cells and liver sinusoidal endothelial cells have been shown to phagocytose human platelets as well as erythrocytes. Several pathways including ASGR1 and CD18-receptor-mediated recognition of human platelets by porcine cells have been identified and may account for Neu5Gc-independent sequestration of platelets in our model. 27, 28 Additionally, alteration of sialic acid profiles on platelet oligosaccharides likely contributes to thrombocytopenia in porcine xenotransplantation; however, an exact role for Neu5Gc has not been explained. 29 Interestingly, and somewhat surprisingly, Butler et al 16 showed that GalTKO.Neu5GcKO pig livers sequestered significantly fewer platelets than GalTKO livers.
One major difference in our study is the use of whole human blood as opposed to washed platelets. Clearly there are multiple signaling pathways that contribute to platelet sequestration, and the use of washed platelets instead of whole blood would remove important known mediators, in particular Fc-mediated-and coagulation cascademediated platelet binding. Specifically, when looking at sialic acid profiles and their effects it is important to note that sialidases are found both on various cell types as well as non-cell bound in plasma.
30
Isolated platelets would be expected to act differently than whole blood; therefore, it is not surprising to us that our results differ from those previously reported. We infer that ultimately solving thrombocytopenia will require a multifaceted approach of both pharmacologic and genetic interventions tested in a stringent model such as ours that simulates clinical application using whole human blood to perfuse the pig organ.
We found that a steep decline in platelet numbers occurred in all xenogeneic experiments within the first 5 minutes but that after 1-hour platelet counts appeared to increase over time in all groups (data not shown). In these experiments and in parallel lung perfusion studies, we find that, after the first hour of a xenogeneic perfusion, au- Thromboxane B2 is elaborated both by activated platelets and by macrophages, which have the highest levels of thromboxane synthase. 32 In our study, the addition of the Neu5GcKO in the absence of the drug regimen (Group 1B vs Group 2B) shows benefit in decreasing TXB2 production. Previous work in our laboratory investigated the effect of anti-GPIb antibody on blocking constitutive activation of human platelets by porcine von Willebrand's factor in liver and lung models, finding some benefit on platelet sequestration and activation. 17, 18 Thromboxane synthase inhibition (which affects both blood platelets, monocytes, and tissue macrophages) and anti-histamines attenuated lung injury. 33 When added to our liver model the drug regimen reduced TXB2 release within each genotype (Group 1A vs 1B and 2A vs 2B). Therefore, we conclude that while Neu5GcKO does not have a dramatic independent effect on platelet sequestration, it may assist in reducing platelet activation, as do the combination of GPIb, thromboxane, and histamine. We predict that this effect will be augmented if other known pathways that mediate platelet sequestration and activation are also addressed, in particular ASGR1, de-sialation, and selectins and other adhesive interactions (GPIb, CD18).
We did not see increases in P-selectin expression, which reflects platelet activation, on the platelets that remained circulating in the perfusate, as we expected to based on our lung model. We attribute this difference to relatively avid scavenging of activated platelets by pig liver relative to the lung, given the profound thrombocytopenia that we saw in all liver perfusion experiments. The isolated peak in CD62P expression at 15 minutes in the GalTKO.hCD46.Neu5GcKO group without drug treatment reflects a single, high result in one experiment, likely spurious.
Transaminase elaboration is used clinically to quantify liver injury.
Censoring the one experiment that had excessively high AST and ALT values for unknown reasons, there was a significant increase in AST in all experiments, with no difference between the two pig liver genotypes or in association with the drug regimen. The gradual rise in ALT throughout pig liver perfusions did not exceed normal physiologic levels. The disproportionate rise in AST with levels in the thousands confirms prior observations. 34 We hypothesize that AST elaboration in part reflects RBC hemolysis as well as hepatocellular injury, an inference supported by elevated LDH levels and an increasing red color of plasma isolates at later experimental time points.
To maximize donor organ utilization, several parallel large animal transplants were performed concurrently. By necessity this did result in relatively small group numbers based on drug regimens. To compensate for this, we have addressed this by analyzing experimental subgroups based on drug regimen. In cases in which there is not a difference based on drug regimen we have combined groups based on genotype, and in cases where drug regimen does appear to exert a difference we have commented on these as separate groups.
The unfortunate corollary to this practice is small sample sizes in some cases.
Additionally, our perfusion durations were shorter than those previously reported by other groups, raising the concern for technical errors. Recent work has used isolated blood components (washed platelets, 6, 16 or isolated red blood cells 26 ) which as discussed above is different from our whole blood system, and the lack of plasma components likely removes deleterious immunologic and complement mediators. Previous studies of human whole blood perfusion of transgenic human decay-accelerating factor (hDAF) pig livers did achieve 72 hours of perfusion. 35 In these works, the hematocrit was noted to reach a nadir of 5.7%
of the initial value at 72 hours. This was not dissimilar to our observed sharp decreases in hematocrit, however, over a shorter time period. A potential explanation for this is that due to our lower starting hematocrits, smaller changes in values were magnified when expressed as a percentage remaining. Additionally, metabolic derangements similar to our study, such as acidosis and hyperkalemia, were observed toward the end of these perfusions.
Our shorter perfusion durations likely resulted from a combination of excess plasma, lower starting hematocrits, stricter termination criteria, and technical aspects. 36 Another small case report using transgenic pigs (CD55/CD59) included two patients who were both bridged to allotransplantation following ex vivo perfusion. 37 Information regarding platelet and red blood cells counts was not reported. In parallel, large animal pig to nonhuman-primate in vivo liver transplant studies had been plagued by short survivals attributed to anemia and thrombocytopenia requiring transfusions. 8, 20 However, long-term survival (25 days) after
GalTKO pig-to-baboon liver xenotransplantation (in the presence of coagulation factor supplementation) has recently been reported. 38 In this case, anemia requiring transfusions was still present, but platelet transfusions were not required and platelet counts recovered spontaneously after eleven days. These results coupled with genetic manipulations leading to decreased platelet consumption during ex vivo porcine liver xenoperfusions, such as asialoglycoprotein receptor 1 knockout, 39 have reaffirmed the potential of transgenic pig livers for clinical use.
In summary, the addition of Neu5GcKO to GalTKO.hCD46 pig liver xenografts appears to contribute a benefit with respect to erythrocyte biology and TXB2 elaboration, without improving survival, modulating platelet sequestration or activation, or attenuating βTG elaboration.
Ultimately, we conclude that a combination of additional genetic and pharmacologic strategies will likely be required to achieve successful therapeutic application of liver xenotransplantation.
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